ArticlePloS one2021
An economic evaluation of the Whole Genome Sequencing source tracking program in the U.S.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- A systematic review of economic evaluations of whole-genome sequencing for the surveillance of bacterial pathogens.Microbial genomics · 2023Pooled it
- Resolution of MALDI-TOF MS compared to whole genome sequencing for the identification of Vibrio parahaemolyticus strains isolated from oysters.Archives of microbiology · 2026Article
- Molecular Insights and Antibiotic Resistance ofFood science & nutrition · 2026Article
- Database resources of the National Center for Biotechnology Information in 2026.Nucleic acids research · 2026Article
- Epidemiology, antimicrobial resistance transmission, and One Health-based prevention of non-typhoidalFrontiers in microbiology · 2026Review
- The impact of integrated genomic surveillance on non-typhoidalThe Lancet regional health. Western Pacific · 2025Article
- Estimating the deferred value of pathogen genomic data for secondary use.Scientific data · 2025Article
- Leveraging innovative diagnostics as a tool to contain superbugs.Antonie van Leeuwenhoek · 2025Review
- Database resources of the National Center for Biotechnology Information in 2025.Nucleic acids research · 2025Article
- Longitudinal surveillance and transmission ofAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- Advances in whole genome sequencing for foodborne pathogens: implications for clinical infectious disease surveillance and public health.Frontiers in cellular and infection microbiology · 2025Review
- Resolution of MALDI-TOF compared to whole genome sequencing for identification ofFrontiers in microbiology · 2025Article
- Detection of antimicrobial resistance via state-of-the-art technologies versus conventional methods.Frontiers in microbiology · 2025Review
- Genomic perspectives on foodborne illness.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Foodborne bacterial pathogens: genome-based approaches for enduring and emerging threats in a complex and changing world.Nature reviews. Microbiology · 2024Review
- PHA4GE quality control contextual data tags: standardized annotations for sharing public health sequence datasets with known quality issues to facilitate testing and training.Microbial genomics · 2024Article
- Genomic perspectives on foodborne illness.medRxiv : the preprint server for health sciences · 2024Article
- A Review on Microbiological Source Attribution Methods of Human Salmonellosis: From Subtyping to Whole-Genome Sequencing.Foodborne pathogens and disease · 2024Review
- Active surveillance of carbapenemase-producing Enterobacterales using genomic sequencing for hospital-based infection control interventions.Infection control and hospital epidemiology · 2024Article
- Approaching pathogenicbioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The U.S. Food and Drug Administration (FDA) created the GenomeTrakr Whole Genome Sequencing (WGS) Network in 2013, as a tool to improve food safety. This study presents an analysis of Whole Genome source tracking implementation on potential food contamination and related illnesses through theoretical, empirical, and cost benefit analyses. We conduct empirical tests using data from FDA regulated food commodity outbreaks garnering FDA response from 1999 through 2019 and examine the effect of the National Center for Biotechnology Information (NCBI) Pathogen detection program of source tracking WGS isolates collected in the U.S. on outbreak illnesses for three pilot pathogens (E. coli, Listeria, and Salmonella). Empirical results are consistent with the theoretical model and suggest that each additional 1,000 WGS isolates added to the public NCBI database is associated with a reduction of approximately 6 illnesses per WGS pathogen, per year. Empirical results are connected to existing literature for a Monte Carlo analysis to estimate benefits and costs. By 2019, annual health benefits are estimated at nearly $500 million, compared to an approximately $22 million investment by public health agencies. Even under conservative assumptions, the program likely broke even in its second year of implementation and could produce increasing public health benefits as the GenomeTrakr network matures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.